Cargando…

Multicentre quantitative (68)Ga PET/CT performance harmonisation

PURPOSE: Performance standards for quantitative (18)F-FDG PET/CT studies are provided by the EANM Research Ltd. (EARL) to enable comparability of quantitative PET in multicentre studies. Yet, such specifications are not available for (68)Ga. Therefore, our aim was to evaluate (68)Ga-PET/CT quantific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huizing, Daphne M. V., Koopman, Daniëlle, van Dalen, Jorn A., Gotthardt, Martin, Boellaard, Ronald, Sera, Terez, Sinaasappel, Michiel, Stokkel, Marcel P. M., de Wit-van der Veen, Berlinda J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6841905/ https://www.ncbi.nlm.nih.gov/pubmed/31705215 http://dx.doi.org/10.1186/s40658-019-0253-z

Ejemplares similares

Feasibility of PET/CT system performance harmonisation for quantitative multicentre (89)Zr studies
por: Kaalep, Andres, et al.
Publicado: (2018)

(177)Lutetium SPECT/CT: Evaluation of collimator, photopeak and scatter correction
por: Huizing, Daphne M. V., et al.
Publicado: (2020)

Feasibility of state of the art PET/CT systems performance harmonisation
por: Kaalep, Andres, et al.
Publicado: (2018)

Early differences in dynamic uptake of (68)Ga-PSMA-11 in primary prostate cancer: A test-retest study
por: olde Heuvel, J., et al.
Publicado: (2021)

Day-to-day variability of [(68)Ga]Ga-PSMA-11 accumulation in primary prostate cancer: effects on tracer uptake and visual interpretation
por: olde Heuvel, Judith, et al.
Publicado: (2020)

A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy
por: Huizing, Daphne M. V., et al.
Publicado: (2020)

Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review
por: Huizing, Daphne Merel Valerie, et al.
Publicado: (2018)

(68)Ga-PSMA Cerenkov luminescence imaging in primary prostate cancer: first-in-man series
por: olde Heuvel, Judith, et al.
Publicado: (2020)

Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient’s therapy course
por: de Vries–Huizing, Daphne M. V., et al.
Publicado: (2021)

Predicting [(177)Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [(68)Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
por: Siebinga, Hinke, et al.
Publicado: (2023)

Predicting the effect of different folate doses on [(68)Ga]Ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling
por: Siebinga, Hinke, et al.
Publicado: (2023)

Harmonisation of PET/CT contrast recovery performance for brain studies
por: Verwer, E. E., et al.
Publicado: (2021)

EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies
por: Aide, Nicolas, et al.
Publicado: (2017)

Performance evaluation of Cerenkov luminescence imaging: a comparison of (68)Ga with (18)F
por: olde Heuvel, J., et al.
Publicado: (2019)

A physiologically based pharmacokinetic model for [(68)Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients
por: Siebinga, Hinke, et al.
Publicado: (2023)

Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy
por: Huizing, Daphne M. V., et al.
Publicado: (2020)

A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of (68)Ga-DOTATATE in patients without neuroendocrine tumors
por: Siebinga, H., et al.
Publicado: (2021)

(68)Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET
por: Brom, Maarten, et al.
Publicado: (2010)

(68)Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas
por: Boertien, Tessel M., et al.
Publicado: (2020)

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

Updating PET/CT performance standards and PET/CT interpretation criteria should go hand in hand
por: Boellaard, Ronald, et al.
Publicado: (2019)

The effect of purification of Ga-68-labeled exendin on in vivo distribution
por: Brom, Maarten, et al.
Publicado: (2016)

Automated synthesis and quality control of [(99m)Tc]Tc-PSMA for radioguided surgery (in a [(68)Ga]Ga-PSMA workflow)
por: Aalbersberg, Else A., et al.
Publicado: (2020)

Brain Imaging of the GLP-1 Receptor in Obesity Using (68)Ga-NODAGA-Exendin-4 PET
por: Deden, Laura N., et al.
Publicado: (2021)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

Prospective Multicentric Assessment of (68)Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET
por: Lugat, Alexandre, et al.
Publicado: (2023)

PET-Based Human Dosimetry of (68)Ga-NODAGA-Exendin-4, a Tracer for β-Cell Imaging
por: Boss, Marti, et al.
Publicado: (2020)

The consequences of a new software package for the quantification of gated-SPECT myocardial perfusion studies
por: van der Veen, Berlinda J., et al.
Publicado: (2010)

Assessment of global cardiac I-123 MIBG uptake and washout using volumetric quantification of SPECT acquisitions
por: van der Veen, Berlinda J., et al.
Publicado: (2012)

Intra-individual qualitative and quantitative comparison of [(68)Ga]Ga-DOTATATE PET/CT and PET/MRI
por: Lens, Géraldine, et al.
Publicado: (2023)

EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems
por: Kaalep, Andres, et al.
Publicado: (2017)

Cyclotron-based production of (68)Ga, [(68)Ga]GaCl(3), and [(68)Ga]Ga-PSMA-11 from a liquid target
por: Rodnick, Melissa E., et al.
Publicado: (2020)

Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review
por: Siebinga, Hinke, et al.
Publicado: (2022)

Voxel-based comparison of [(68)Ga]Ga-RM2-PET/CT and [(68)Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
por: Fassbender, Thomas Franz, et al.
Publicado: (2020)

Artificial intelligence-based (68)Ga-DOTATOC PET denoising for optimizing (68)Ge/(68)Ga generator use throughout its lifetime
por: Quak, Elske, et al.
Publicado: (2023)

(68)Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism
por: Boss, Marti, et al.
Publicado: (2022)

Meningiomas: A Comparative Study of (68)Ga-DOTATOC, (68)Ga-DOTANOC and (68)Ga-DOTATATE for Molecular Imaging in Mice
por: Soto-Montenegro, María Luisa, et al.
Publicado: (2014)

Quantitative [(68)Ga]Ga-PSMA-11 PET biomarkers for the analysis of lesion-level progression in biochemically recurrent prostate cancer: a multicentre study
por: Kendrick, Jake, et al.
Publicado: (2023)

Standardized image quality for (68)Ga-DOTA-TATE PET/CT
por: Cox, Christina P. W., et al.
Publicado: (2020)

(68)Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study
por: van Boxtel, Wim, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5of8g8tdpemavr1h24t0dgkivl